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CXCR2 chemokine receptor antagonism enhances DOP opioid receptor
function via allosteric regulation of the CXCR2–DOP receptor heterodimer
Geraldine PARENTY, Shirley APPELBE and Graeme MILLIGAN1
Molecular Pharmacology Group, Division of Biochemistry and Molecular Biology, Institute of Biomedical and Life Sciences, University of Glasgow, Glasgow G12 8QQ, Scotland, U.K.
Opioid agonists have a broad range of effects on cells of
the immune system, including modulation of the inﬂammatory
response, and opioid and chemokine receptors are co-expressed
by many white cells. Hetero-oligomerization of the human DOP
opioid and chemokine CXCR2 receptors could be detected
followingtheirco-expressionbyeachofco-immunoprecipitation,
three different resonance energy transfer techniques and the
construction of pairs of individually inactive but potentially
complementary receptor G-protein α subunit fusion proteins.
Although DOP receptor agonists and a CXCR2 antagonist had no
inherent afﬁnity for the alternative receptor when either receptor
was expressed individually, use of cells that expressed a DOP
opioid receptor construct constitutively, and in which expression
of a CXCR2 receptor construct could be regulated, demonstrated
thattheCXCR2antagonistenhancedthefunctionofDOPreceptor
agonistsonlyinthepresenceofCXCR2.Thiseffectwasobserved
for both enkephalin- and alkaloid-based opioid agonists, and
the effective concentrations of the CXCR2 antagonist reﬂected
CXCR2 receptor occupancy. Entirely equivalent results were
obtained in cells in which the native DOP opioid receptor was
expressed constitutively and in which expression of the isolated
CXCR2 receptor could be induced. These results indicate that
aCXCR2receptorantagonistcanenhancethefunctionofagonists
at a receptor for which it has no inherent direct afﬁnity by acting
as an allosteric regulator of a receptor that is a heterodimer
partner for the CXCR2 receptor. These results have novel and
important implications for the development and use of small-
molecule therapeutics.
Key words: allosterism, chemokine, G-protein-coupled receptor,
heterodimer, opioid.
INTRODUCTION
It has become increasingly clear in recent times that opioid
agonists have a broad range of effects on cells of the immune
system, including modulation of the inﬂammatory response [1].
Opioid receptor levels are regulated by peripheral inﬂammation
[2], and it is thought that highly peripherally selective opioid
agonists may provide a therapeutic approach for the treatment of
inﬂammation and inﬂammatory pain (see [3] for review). Opioids
function via three molecularly deﬁned receptor subtypes, the
DOP, KOP and MOP receptors [4]. These are all members of
the rhodopsin-like family of GPCRs (G-protein-coupled
receptors). As well as their characterized expression patterns in
the central and peripheral nervous systems they are expressed
on a wide range of white blood cells, including macrophages
and neutrophils [5]. Various opioid agonists are known to
produce chemotactic responses in white cells, and to modulate
chemotaxis induced by a range of chemokines. Chemokines and
their receptors are also integrators of pain and inﬂammation [6–
8] and there is a clear capacity for heterologous modiﬁcation
and desensitization between co-expressed chemokine and opioid
receptors [9–11]. Receptors for chemokine ligands also belong
to the rhodopsin-like GPCR family, and one further potential
mechanism that may contribute to the effects outlined above
is direct interactions between chemokine and opioid receptors.
At least for the CCR5 chemokine receptor, a capacity to co-
immunoprecipitate each of the DOP, KOP and MOP receptors
from both human and monkey lymphocytes [12] provided
preliminary evidence of such interactions, and direct protein–
protein contacts between CCR5 and the MOP receptor have been
conﬁrmed independently [13].
The closely related CXCR1 and CXCR2 receptors [14] share
a common agonist ligand in IL-8 (interleukin 8; also called
CXCL8). They are widely co-expressed on immune cells, includ-
ing neutrophils, CD8(+) T-cells and mast cells, and allosteric
inhibitorsofthesereceptorshavebeensuggestedtoofferageneral
means to inhibit polymorphonuclear cell recruitment in vivo
[15]. Opioid agonists inhibit IL-8-induced chemotaxis of human
neutrophils,andopioidagonistsareabletocausephosphorylation
of CXCR1 and CXCR2 receptors [9]. Interestingly, CXCR2, but
not CXCR1, is expressed by a variety of neurones and astrocytes
[14] and may be involved in the directed migration of speciﬁc
subsets of neurones.
AlthoughitwasbelievedformanyyearsthatGPCRsfunctioned
exclusively as monomers, a growing consensus has challenged
thisview.Indeed,itisnowwidelybelievedthattheminimalinsitu
functional unit for a GPCR is a dimer and that further, higher-
order, oligomeric structures may exist [16–19]. Much evidence
suggests that for many GPCRs dimerization/oligomerization
occurs during synthesis and maturation within the endoplasmic
reticulum [20,21] prior to plasma membrane delivery. This model
would explain why many GPCRs appear to be constitutively
formed dimers/oligomers. It is also increasingly accepted that at
leastcertainGPCRshavethecapacitytoformheterodimers/oligo-
mers (i.e. dimers formed between two different GPCR gene
products)[16,22].Suchheterodimers/oligomersmayhavedistinct
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functional and pharmacological properties and have been sug-
gestedtooffernovelsetsoftargetsfortherapeuticsmall-molecule
drugdesign[22,23].AlthoughtheCXCR1receptorwasoriginally
reported not to homodimerize or to heterodimerize with the
CXCR2receptor[24],Wilsonetal.[21]recentlyemployedawide
range of biochemical and biophysical approaches to demonstrate
the capacity of both CXCR1 and CXCR2 to homodimerize and
to show that these two GPCRs were able to form heterodimers as
effectively as homodimers.
It has recently been demonstrated that selective ligands at pairs
of GPCRs that heterodimerize have the potential to modulate
ligand effects at the partner GPCR via allosterism (see [25]
for review). Studies on heterodimerization between the CCR2b
and CCR5 chemokine receptors have demonstrated the ability of
CCR5-speciﬁc ligands, that are unable to compete for the binding
of the CCR2 selective ligand MCP-1 (monocyte chemoattractant
protein 1) on cells expressing CCR2b alone, to prevent efﬁciently
MCP-1 binding when the two receptors are co-expressed [26].
Similarly,co-expressionoftheorphanGPCR,GPR50,alongwith
the melatonin MT1 receptor inhibits binding of [
125I]melatonin
to the MT1 receptor [27].
Inthepresentstudyweusearangeofapproachestodemonstrate
the capacity for heterodimerization between the human CXCR2
and DOP opioid receptors and show that a CXCR2 antagonist
enhancesthefunctionofbothpeptideandalkaloid-basedagonists
at the DOP receptor via an allosteric mechanism when the two
receptors are co-expressed. This is despite the CXCR2 ligand
having no signiﬁcant afﬁnity to interact directly with the DOP
receptor.
EXPERIMENTAL
Materials
[15,16-
3H]Diprenorphine (50 Ci/mmol) and [
35S]GTP[S] (1250
Ci/mmol) were from PerkinElmer Life Science. DADLE
(D-Ala
2,Leu
5-enkephalin), DPDPE ([D-Pen
2,5]-enkephalin) and
pertussis toxin were from Sigma–Aldrich. SB225002 was from
Calbiochem, and SNC162 [28] was from Tocris. All reagents for
BRET
2 (bioluminescenceresonanceenergytransfer)studieswere
from Packard Biosciences.
Antibodies/antisera
The anti-Gαi1-2 antiserum (SG) has been described previously
[29]. The mouse monoclonal anti-FLAG antibody (M2) was from
Sigma–Aldrich. The rabbit polyclonal anti-c-Myc antiserum was
from Cell Signalling Technology.
Molecular Constructs
hDOP–C352I Gαi2 (where h indicates the human form),
V150E,V154D hDOP–C352I Gαi2 and hDOP–G204A,C352I Gαi2
were constructed as in Pascal and Milligan [30], except that
C352I Gαi2 replaced C351I Gαi1. CXCR2–C352I Gαi2 and I148E
CXCR2–C352I Gαi2 were constructed using similar approaches.
FLAG–hCXCR2, c-Myc–hCXCR2 and forms of the CXCR2
C-terminally tagged with auto-ﬂuorescent proteins or Renilla
luciferase have been described previously [21], as have the
equivalent modiﬁed forms of hDOP [31]. The nomenclature for
the molecular constructs employed is shown in Table 1.
Fluorescent microscopy and FRET (ﬂuorescence resonance energy
transfer) imaging in living cells
Cells were grown on poly-D-lysine-treated coverslips and
transiently transfected with appropriate eCFP (enhanced cyan
Table 1 Characteristics of the molecular constructs employed
Construct Description
FLAG–hCXCR2 N-terminal FLAG-tagged form of human CXCR2
c-Myc–hCXCR2 N-terminal c-Myc-tagged form of human CXCR2
hCXCR2–eCFP C-terminal eCFP-tagged form of human CXCR2
hCXCR2–GFP2 C-terminal eGFP2-tagged form of human CXCR2
hCXCR2-Renilla luciferase Human CXCR2 C-terminally tagged with Renilla luciferase
hCXCR2–C352I Gαi2 Fusion protein in which a pertussis-toxin-insensitive form
of Gαi2 is linked to the C-terminus of human CXCR2
I148E hCXCR2–C352I Gαi2 Fusion protein in which a pertussis-toxin-insensitive form
of Gαi2 is linked to the C-terminus of human CXCR2
containing a I148E mutation that prevents
receptor-mediated activation of the G-protein
c-Myc–hDOP N-terminal c-Myc-tagged form of the human DOP receptor
hDOP–eYFP C-terminal eGFP2-tagged form of the human DOP receptor
hDOP–GFP2 C-terminal eGFP2-tagged form of the human DOP receptor
hDOP–Renilla luciferase Human DOP receptor C-terminally tagged with Renilla
luciferase
hDOP–C352I Gαi2 Fusion protein in which a pertussis-toxin-insensitive form
of Gαi2 is linked to the C-terminus of the human DOP
receptor
V150E,V154D hDOP–C352I Gαi2 Fusion protein in which a pertussis-toxin-insensitive form
of Gαi2 linked to the C-terminus of a mutant human DOP
receptor that can bind ligands but not transduce a signal
hDOP–G204A,C352I Gαi2 Fusion protein in which a pertussis-toxin-insensitive form
of Gαi2 that cannot be activated is linked to the
C-terminus of the human DOP receptor
ﬂuorescent protein)/eYFP (enhanced yellow ﬂuorescent protein)
fusion proteins. Coverslips were placed into a microscope
chamber containing physiological saline solution [130 mM NaCl,
5 mM KCl, 1 mM CaCl2,1 m MM g C l 2, 20 mM Hepes and
10 mM D-glucose (pH 7.4)]. Cells were visualized using a Nikon
Eclipse TE2000-E ﬂuorescence inverted microscope and images
were obtained individually for eYFP, eCFP and FRET ﬁlter
channels using an Optoscan monochromator (Cairn Research)
and a dichroic mirror 86002v2bs (Chroma). The ﬁlter sets
used were: eYFP (excitation: 500/5 nm; emission: 535/30 nm),
eCFP (excitation: 430/12 nm; emission: 470/30 nm) and FRET
(excitation: 430/12 nm; emission: 535/30 nm). The illumination
time was 250 ms and binning modes 2·2. MetaMorph imaging
software was used to quantify the FRET images using the
sensitized FRET method. Corrected FRET was calculated using
a pixel-by-pixel methodology using the equation:
FRETc = FRET − (coefﬁcient B × eCFP)
−(coefﬁcient A × eYFP)
where eCFP, eYFP and FRET values correspond to background
corrected images obtained through the eCFP, eYFP and FRET
channels. B and A correspond to the values obtained for the
eCFP (donor) and eYFP (acceptor) bleedthrough co-efﬁcients
respectively, calculated using cells singly transfected with either
the eCFP or eYFP protein alone. To correct the FRET levels
for the various amounts of donor (eCFP) and acceptor (eYFP),
normalized FRET was calculated using the equation:
FRETn = FRETc/(eCFP × eYFP)
where FRETc, eCFP and eYFP are equal to the ﬂuorescence
values obtained from single cells.
c   The Authors Journal compilation c   2008 Biochemical Society © 2008 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commerical use, distribution and reproduction in any medium, provided the original work is properly cited.Allosterism and CXCR2/opioid receptor interactions 247
Tr (time-resolved) FRET
For tr-FRET, 10 cm
2 dishes of HEK (human embryonic kidney)-
293 cells were transfected to express N-terminally c-Myc- or
FLAG-tagged forms of hCXCR2 and/or hDOP individually or in
combination. At 48 h after transfection, the cells were harvested.
Cell pellets were resuspended in 200 μl of ice-cold PBS. Anti-
c-Myc Eu
3+ and anti-FLAG APC (allophycocyanin) antibodies
[21,31] were diluted in 50% newborn calf serum/50% PBS to
ﬁnal concentrations of 5 nM and 15 nM respectively. Samples
weremixedandincubatedonarotatingwheelatroomtemperature
(22◦C) for 2 h while covered in aluminium foil to minimize
exposure of the ﬂuorophores to light. Samples were centrifuged
at 1000 g for 1 min and the antibody mix was removed from
the cell pellet. The pellet was then washed twice in ice-cold
PBS and resuspended in 250 μl of PBS. To measure the energy
transfer, 40 μl of each sample was dispensed in triplicate into
a black 384-well plate. Blank wells containing PBS were also
included. Tr-FRET was determined using a Victor
2 plate reader
(Packard Bioscience). Excitation was at 340 nm and emission
ﬁlters generated data representing donor (615 nm) and acceptor
(665 nm) ﬂuorescence. Normalized FRET was calculated using
the equation:
Normalized FRET = [(A665 − BLK)/D615] − C
where A665 is the ﬂuorescent emission from the acceptor, D615
is the ﬂuorescent emission from the donor and BLK represents
the background reading at 665 nm from wells containing PBS. C
representsthecross-talkbetweenthedonorandacceptorwindows
for the samples incubated with only anti-c-Myc Eu
3+ and is equal
to (A665 −BLK)/D615.
Saturation BRET2 studies
In saturation BRET
2 experiments, cells were transfected with a
constant amount of the energy donor (Renilla luciferase) con-
structandvaryingamountsofenergyacceptor[GFP
2 (greenﬂuor-
escent protein) construct. BRET
2 was assessed using the
luciferase substrate DeepBlueC in intact cells. Cells were also
harvested,membranespreparedanddilutedto0.5 mg/ml.Lumin-
escence and ﬂuorescence measurements were then obtained to
measure construct expression. Then, 50 μl of cell membranes
were dispensed into white-walled 96-well plates (PerkinElmer)
for luminescence measurements and black-walled 386-well
plates (Costar) for ﬂuorescence measurements. For luminescence
measurement5 μMh-coelenterazinewasaddedandtheplatewas
incubated at room temperature for 30 min prior to measurement
at 410 nm using a Mithras LB 940. GFP
2 ﬂuorescence was
assessed using a Victor
2 1420 Multilabel counter (PerkinElmer).
Fluorescence readings were corrected for endogenous ﬂuor-
escenceofHEK-293cellmembranesalone.BRET
2 readingswere
correctedforenergytransferresultingfrombleedthroughofsignal
from the Renilla luciferase construct expressed alonebut detected
in the GFP
2 channel. Graphpad Prism 4 was used to analyse data
using a one-site binding hyperbola equation yielding BRETMAX
and BRET50 values (where BRETMAX is the maximal BRET
signal and BRET50 is half the maximal BRET signal).
Cell transfection and treatment
HEK-293 cells were transfected transiently using Lipofect-
amine
TM reagent (Gibco Life Technologies) or Gene Juice
(Novagen) and the appropriate cDNA(s) according to the manu-
facturer’s instructions. Where appropriate, cells were treated with
pertussis toxin (25 ng/ml) for 16–18 h prior to harvest.
[3H]Diprenorphine binding
The expression of hDOP–G-protein fusions was assessed by
measuring the speciﬁc binding of [
3H]diprenorphine in cell-
membrane preparations. Non-speciﬁc binding was assessed by
the addition of 100 μM naloxone. Samples were incubated
for 1 h at 25◦C and bound ligand was separated from free
ligand by vacuum ﬁltration through GF/B ﬁlters pre-treated with
0.3% polyethyleneimine in TEM (10 mM Tris/HCl, 0.1 mM
EDTA and 10 mM MgCl2, pH adjusted to 7.5). Bound ligand
was estimated by liquid scintillation spectroscopy. Competition
studies were conducted with 1 nM [
3H]diprenorphine and a range
of concentrations of other ligands. Data were analysed using
GraphPad Prism software. Saturation data were ﬁtted to non-
linear regression curves.
[35S]GTP[S] binding studies
Experiments were initiated by adding the assay buffer mix
[20 mM Hepes (pH 7.4), 3 mM MgCl2, 100 mM NaCl, 10 μM
GDPand0.2 mMascorbicacid]containing50nCiof[
35S]GTP[S]
in the presence or absence of ligands to deﬁned amounts of
membranes.Non-speciﬁcbindingwasdeterminedinthepresence
of 100 μM GTP[S]. The reaction was incubated for 15 min at
30◦C and terminated by adding 1 ml of ice-cold stop buffer
[20 mM Hepes (pH 7.4), 3 mM MgCl2 and 100 mM NaCl]. The
samples were centrifuged for 15 min at 16000 g at 4◦Ca n d
the resulting pellets were resuspended in solubilization buffer
(100 mM Tris/HCl, 200 mM NaCl, 1 mM EDTA and 1.25%
Nonidet P40, pH adjusted to 7.4) plus 0.2% SDS. Samples were
pre-cleared with Pansorbin for 1 h at 4◦C and centrifuged for
2 minat16000 g.SupernatantwasaddedtoamixofProteinGand
the anti-Gαi1/Gαi2 antiserum [29] and was left rotating overnight
at 4◦C for immunoprecipitation. The immunocomplexes were
washed twice with ice-cold solubilization buffer and bound
[
35S]GTP[S] was measured.
Co-immunoprecipitation
Cells were resuspended in 1 ml of 1·RIPA [radio-immunopre-
cipitation assay; 50 mM Hepes (pH 7.4), 150 mM NaCl, 0.5%
sodium deoxycholate, 0.1% SDS, 1% Triton X-100, 100 mM
NaF, 5 mM EDTA, 0.1 mM NaPO4 and 5% ethylene glycol]
buffer and rotated for 60 min at 4◦C to allow lysis. The samples
were centrifuged at 14000 g for 10 min at 4◦C and the super-
natant was retained. A 50 μl aliquot of a Protein G–
Sepharose/PBS slurry was added to the supernatant and rotated
forafurther60 min at4◦Ctopre-clear.Sampleswerecentrifuged
at 14000 g for 10 min at 4◦C. The supernatant was conserved
and the protein concentration was measured using the BCA
(bicinchoninic acid) assay method. Samples were equalized to
1 μg/μl. Target proteins were then immunoprecipitated from
500 μl aliquots of samples by incubation with 20 μl of Protein
G–Sepharose and the appropriate antibody/antiserum overnight
at 4◦C on a rotating wheel. Immune complexes were isolated by
centrifugation at 14000 g for 1 min and washed twice with RIPA
buffer. Proteins were eluted from the Protein G–Sepharose by the
addition of 30–50 μl of Laemmli buffer and heated for 4 min at
85◦C. The eluates were then loaded on to SDS/PAGE gels.
Construction of Flp-In T-REx HEK-293 cell lines
The basic protocol used to generate Flp-In T-REx HEK-293 cell
lines that constitutively express one GPCR and can be induced
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to express a second has been described previously [32–34]. In
brief, cells were maintained in DMEM (Dulbecco’s modiﬁed
Eagle’s medium) without sodium pyruvate, 4500 mg/l glucose
and L-glutamine supplemented with 10% (v/v) fetal calf serum,
1% antibiotic mixture and 10 μg/ml blasticidin at 37◦Ci n
a humidiﬁed atmosphere of air/CO2 (19:1). To generate Flp-
In T-REx HEK-293 cell lines able to inducibly express c-
Myc–I148E CXCR2–C352I Gi2α or VSV-G–CXCR2 (where
VSV-G is vesicular-stomatitis-virus glycoprotein), cells were
transfected with a mixture containing the desired receptor cDNA
in pcDNA5/FRT/TO vector and the pOG44 vector (1:9) using
Lipofectamine
TM (Invitrogen) according to the manufacturer’s
instructions. After 48 h, the medium was changed to medium
supplemented with 200 μg/ml hygromycin B to initiate selection
of stably transfected cells. To constitutively express FLAG–
hDOP–G204A, C352I Gαi2 or FLAG–hDOP in cell lines already
capable of the induction of expression of a second construct, the
appropriate cells were further transfected with the desired recep-
tor cDNA in pcDNA3 as described above, and resistant cells were
selected in the presence of 1 mg/ml G418. Resistant clones
were screened for receptor expression by immunocytochemical
analysis. Cells were treated with 1 μg/ml doxycycline 6–96 h
before assays to induce expression of receptors and receptor
constructs cloned into the Flp-In locus.
Immunostaining protocol
Cells were grown on to coverslips, and 24 h later medium was
removedandthecellswereincubatedwith20 mMHepes/DMEM
containingtheappropriatedilutionofprimaryantibodyfor40 min
at 37◦Ci n5 % CO2. Following three washes with PBS, cells
were ﬁxed by incubating with 4% paraformaldehyde in PBS/5%
sucrose for 10 min at room temperature. Following three further
washes, cells were permeabilized with 0.15% Triton X-100/3%
non-fat dried skimmed milk/PBS for 10 min. The coverslips were
incubated with a secondary antibody (5 μg/ml) conjugated to an
AlexaFluor®-594ﬂuorophore.Followingincubationfor1 h,cells
were washed twice in 0.15% Triton X-100/3% non-fat dried
skimmed milk/PBS and three times in PBS. Coverslips were then
mounted on to microscope slides with 40% glycerol in PBS.
Confocal laser scanning microscopy
Cells were imaged using a laser scanning confocal microscope
(Zeiss LSM 5 Pascal) equipped with a 63× oil-immersion Plan
Fluor Apochromat objective lens with a numerical aperture of
1.4. A pinhole of 20 and an electronic zoom of 1 or 2.5 was used
(Carl Zeiss). The excitation laser line for GFP and eYFP was the
488 nm argon laser with detection via a 505–530 band pass ﬁlter.
Alexa Fluor®-594 label was excited using a 543 nm helium/neon
laser and detected via a 560 nm long-pass ﬁlter. The images were
manipulated using MetaMorph imaging software (version 6.1.3;
Universal Imaging).
RESULTS
ToexaminepotentialinteractionsbetweenthechemokineCXCR2
and DOP opioid receptors, the human forms of these receptors
were modiﬁed to incorporate either the FLAG or c-Myc epitope
tag sequences at the N-terminus. We have previously shown the
capacityofeachofthesereceptorstoformhomodimers/oligomers
via co-immunoprecipitation studies [21,31]. Expression in HEK-
293cellsofFLAG–hCXCR2resultedinimmunologicaldetection
in lysates of these cells of a 34 kDa polypeptide with a degree
of micro-heterogeneity (Figure 1) representing differential N-
Figure 1 Co-expression of FLAG–hCXCR2 and c-Myc–hDOP allows their
co-immunoprecipitation
HEK-293 cells were mock-transfected (Mock) or transfected to transiently express FLAG–
hCXCR2, c-Myc–hDOP or both (Co-transfected). Samples containing either FLAG–hCXCR2
or c-Myc–hDOP were also mixed (Mix). Conﬁrmation of expression of the appropriate con-
structs was obtained by immunoblotting cell lysates with either anti-c-Myc or anti-FLAG anti-
bodies (lower panels). Cell lysates were subsequently immunoprecipitated using anti-FLAG.
Immunoprecipitated samples were resolved by SDS/PAGE and immunoblotted with an
anti-c-Myc antibody (upper panel). Two further experiments produced similar results. IP,
immunoprecipitation. The molecular mass in kDa is indicated on the left-hand side.
glycosylation [21]. Expression of c-Myc–hDOP resulted in the
presence of a c-Myc-reactive polypeptide with a molecular
mass of 60 kDa (Figure 1). Only with co-expression of FLAG–
hCXCR2 and c-Myc–hDOP did immunoprecipitation with
an anti-FLAG antibody result in co-immunoprecipitation of
c-Mycimmunoreactivity(Figure1)and,eveninSDS/PAGE,such
immunoreactivity migrated with sizes ranging from 60 kDa to
complexes with a substantially higher apparent molecular mass.
Because the N-terminal region of GPCRs that are effectively
delivered to the cell surface is expected to be extracellular, we
also took advantage of the introduced N-terminal tags to perform
tr-FRET studies in intact HEK-293 cells [21,31] to detect pro-
tein complexes containing both receptors at the cell surface. Co-
expression of c-Myc–hCXCR2 and FLAG–hDOP followed by
the addition of a combination of Eu
3+-labelled anti-c-Myc, to act
as a long-lived energy donor, and APC-labelled anti-FLAG, to
act as a potential energy acceptor, resulted in strong tr-FRET and
output of light at 665 nm when samples were illuminated with
320 nm light (Figure 2A). This did not occur when HEK-293 cell
populations individually expressing either c-Myc–hCXCR2 or
FLAG–hDOPwerecombinedpriortoadditionofthecombination
of Eu
3+-labelled and APC-labelled antibodies (Figure 2A). Fur-
thermore, the extent of energy transfer following co-expression
of c-Myc–hCXCR2 and FLAG–hDOP was virtually the same
as when c-Myc–hDOP and FLAG–hDOP were co-expressed to
generate tr-FRET competent, cell-surface hDOP homodimers
(Figure 2A). We have also previously shown that in-frame
fusion of auto-ﬂuorescent proteins to the C-terminus of each
of hCXCR2 [21] and hDOP [31,35] does not signiﬁcantly alter
the function or pharmacology of these receptors. Co-expression
of hCXCR2–eCFP and hDOP–eYFP resulted in a capacity to
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Figure 2 FRET and BRET studies conﬁrm hetero-interactions between co-expressed hCXCR2 and hDOP receptors
(A) shows tr-FRET. c-Myc–hDOP and FLAG–hDOP or c-Myc–hCXCR2 and FLAG–hDOP were expressed individually in HEK-293 cells that were then mixed (mix) or the two receptors were
co-expressed (Co). Following addition of a combination of Eu3+-labelled anti-c-Myc, to act as a long-lived energy donor, and APC-labelled anti-FLAG, to act as a potential energy acceptor, to intact
cells tr-FRET was monitored as described in the Experimental section. (B) shows FRET imaging. hDOP–eYFP (eYFP) was transiently expressed in HEK-293 cells with (lower panels) or without
(upper panels) hCXCR2–eCFP (eCFP) and ﬂuorescence imaged. Raw FRET (FRET) and calculated normalized FRET (right-hand panels) was then assessed as described in the Experimental section.
(C) shows saturation BRET2 studies. hCXCR2–Renilla luciferase and hCXCR2–GFP2 (), hCXCR2–Renilla luciferase and hDOP–GFP2 () or hDOP–Renilla luciferase and hDOP–GFP2 ()w e r e
transiently co-expressed in HEK-293 cells. Following addition of the luciferase substrate/BRET2 energy donor DeepBlueC, BRET measurements were made. Donor and acceptor ratios were assessed
as described in the Experimental section. Each experiment is representative of three.
image eCFP to eYFP FRET inindividual single cells (Figure2B),
providing further evidence for direct hCXCR2–hDOP inter-
actions. Estimates of the relative afﬁnities of GPCRs to interact
can be obtained from ‘saturation’ BRET studies [36,37]. In such
experiments, forms of GPCRs C-terminally tagged with Renilla
luciferase and with an autoﬂuorescent protein that is able to act
as an energy acceptor of light emitted from substrate oxidation
by the luciferase are co-expressed in various ratios and the
BRET signal is monitored. Co-expression of hCXCR2–Renilla
luciferase and hCXCR2–GFP
2 in HEK-293 cells resulted in
BRET following addition of the luciferase substrate DeepBlueC
(Figure 2C). At low energy acceptor (hCXCR2–GFP
2)t oe n e r g y
donor (hCXCR2–Renilla luciferase) ratios the BRET signal
increased with increasing [acceptor] to [donor] ratios, but this
asymptoticallyapproachedamaximalvalueathigher[acceptor]to
[donor] ratios (Figure 2C). Half-maximal BRET signal (BRET50)
was achieved at an [acceptor] to [donor] ratio of 1.6+ −0.1.
Co-expression of hDOP–Renilla luciferase and hDOP–GFP
2
also generated BRET signals that saturated with increasing
[acceptor]to[donor]ratios,inthiscasewithBRET50 =2.2+ −0.07.
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Figure 3 hDOP–Gαi2 fusion proteins are activated by DADLE but not by
SB225002
(A) A hDOP-C352I Gαi2 fusion protein was expressed transiently in HEK-293 cells. Following
pertussis-toxin treatment (25ng/ml for 16h) and membrane preparation, basal binding of
[35S]GTP[S] in Gαi2 immunoprecipitates (Basal) and its regulation by DADLE (10−6M),
concentrations of SB225002 from 10−5–10−9M and DADLE (10−6M)+SB225002 (10−5M)
was assessed. (B) V150E,V154D hDOP–C352I Gαi2 and hDOP–G204A,C352I Gαi2 were
co-expressed transiently in HEK-293 cells. Following pertussis-toxin treatment (25ng/ml for
16h)andmembranepreparation,bindingof[35S]GTP[S]inGαi2immunoprecipitatesinresponse
to the same ligands as in (A) was measured. Values represent means+ −S.E.M. (n=3).
Co-expression of hDOP–Renilla luciferase with hCXCR2–GFP
2
generated BRET signals that saturated, and in this case BRET50
was 0.34+ −0.02 (Figure 2C). These results are consistent with
hCXCR2–hDOP hetero-interactions occurring with an even
higher afﬁnity than the corresponding hCXCR2–hCXCR2 and
hDOP–hDOP homo-interactions.
Over time, we have generated a wide range of GPCR–G-pro-
tein fusion constructs [38,39]. These allow production, from
single open reading frames, of bi-functional polypeptides con-
taining the sequence of both a receptor and a G-protein. A
C352I [40,41] pertussis-toxin-insensitive variant of Gαi2 was
linked in-frame to the C-terminal tail of the hDOP receptor.
Following transient expression in HEK-293 cells, treatment with
pertussis toxin (25 ng/ml for 16 h), to cause ADP-ribosylation of
endogenously expressed Gαi G-proteins, and membrane prepara-
tion,thesyntheticenkephalinDADLE(10
−6M)causeda4–5-fold
increaseinthebindingof[
35S]GTP[S]inGαi2 immunoprecipitates
(Figure 3A). By contrast, the non-peptide CXCR2 antagonist
SB225002 [42] had no effect at concentrations from 10
−9–
10
−5M and, indeed, at 10
−5M it had a limited capacity to inhibit
the stimulatory effect of DADLE (Figure 3A). The capacity of
both DADLE and SB225002 to compete with [
3H]diprenorphine
for binding to the hDOP–C352I Gαi2 fusion protein indicated a
pKi forDADLEof9.0+ −0.09,whereasforSB225002thepKi was
>4.0 (results not shown). Pairs of GPCR–G-protein fusions that
are individually both inactive due to the introduction of mutations
can reconstitute function when co-expressed if the GPCRs form a
dimer and if one of the fusion proteins is mutated in the receptor
whereas the other contains the inactivating mutation in the G-
protein[30].VariantsofhDOP–C352IGαi2 thatdidnotmodifythe
ligand-binding domain but failed to increase signiﬁcantly binding
of [
35S]GTP[S] in response to DADLE were produced by mut-
ation of either V150E+V154D in the receptor element or by
introduction of a G204A mutation into Gαi2 (Figure 3B). As
demonstratedpreviouslyfortheequivalenthDOP–C351IGαi1 mu-
tants[30],co-expressionofV150E,V154DhDOP–C352IGαi2 and
hDOP–G204A,C352I Gαi2 reconstituted the ability of DADLE
to stimulate binding of [
35S]GTP[S] in membranes of pertussis-
toxin-treated HEK-293 cells, whereas SB225002 was again
unable to replicate this effect (Figure 3B). The effect of DADLE
required co-expression of the two individually non-responsive
fusion constructs. Simple mixing of membranes expressing each
construct individually did not result in a substantial increase in
bindingof[
35S]GTP[S]inresponsetoDADLE(resultsnotshown,
but see [30]).
We next generated a hCXCR2–C352I Gαi2 fusion construct.
Following transient expression in HEK-293 cells, pertussis-
toxin treatment and membrane preparation, IL-8 was able to
promote binding of [
35S]GTP[S] in Gαi2 immunoprecipitates in
a concentration-dependent manner with a pEC50 of −7.4+ −0.2
(Figure4A).ThiseffectofIL-8was blockedbytheco-additionof
SB225002(Figure4B),whereaseachofDADLE,theDOPopioid
receptor selective DPDPE and the highly DOP receptor selective
small molecule SNC162 [28] were unable to promote binding
of [
35S]GTP[S] to the hCXCR2–C352I Gαi2 fusion (Figure 4B).
As noted for the hDOP–C352I Gαi2 construct, introduction of the
G204A mutation into the G-protein element of the hCXCR2–
C352I Gαi2 fusion protein essentially eliminated the response to
IL-8 (Figure 4C). The same was true when, based on sequence
comparisons and a central role for hydrophobic residues in the
second intracellular loop of class A GPCRs in agonist activation
of G-proteins [43], an I148E hCXCR2–C352I Gαi2 construct was
generated and expressed (Figure 4C).
FLAG–hDOP-G204A,C352I Gαi2 was next expressed stably
and constitutively in Flp-In T-REx HEK-293 cells that harboured
c-Myc–I148E-CXCR2-C352I Gαi2 at the Flp-In locus and indivi-
dual clones were isolated. These cells should allow c-Myc–
I148E-CXCR2-C352I Gαi2 expression to be controlled in an
entirely tetracycline/doxycycline ‘on’ fashion. This expectation
was conﬁrmed via immunocytochemistry. Although plasma-
membrane-localized anti-FLAG immunoreactivity was observed
in these cells both with and without treatment with doxycycline
(Figure 5A), anti-CXCR2 reactivity was only observed following
doxycycline treatment (Figure 5A) and this overlapped strongly
with the anti-FLAG signal (Figure 5A). DADLE (10
−6M)
promoted binding of [
35S]GTP[S] in Gαi2 immunoprecipitates
from membranes of pertussis-toxin-treated cells of this clone
that had been exposed to doxycycline, but not in those that had
not been treated with doxycycline (Figure 5B). This occurred
in a concentration-dependent manner with a pEC50 =−7.2
(Figure 5C). This can only reﬂect guanine-nucleotide exchange
on the C352I Gαi2 linked to c-Myc–I148E CXCR2 and is entirely
consistent with the other observations of hCXCR2–hDOP opioid
receptor hetero-oligomerization (Figures 1 and 2). Although
withouteffectintheabsenceofDADLE,co-additionofSB225002
(10
−6M) resulted in higher levels of DADLE-stimulated
[
35S]GTP[S] binding without altering the potency of the opioid
agonist (pEC50 =−7.1) (Figure 5C). When similar experiments
were performed with a single concentration of DADLE (10
−6M),
increasing concentrations of SB225002 resulted in an increase in
DADLE-stimulatedbindingof[
35S]GTP[S]withapEC50 of−7.2
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Figure 4 Analysis of hCXCR2–C352I Gαi2 fusion proteins
(A)hCXCR2–C352IGαi2 wasexpressedtransientlyinHEK-293cells.Followingpertussis-toxin
treatment (25ng/ml for 16h) and membrane preparation, binding of [35S]GTP[S] in Gαi2
immunoprecipitates was measured in the presence of various concentrations of IL-8.
(B)[ 35S]GTP[S] binding studies were performed as in (A) in the presence of 3×10−7M
IL-8, or 10−6M of each of DADLE, DPDPE or SNC162 (open bars). In the solid bars the
experiments were repeated with the addition of 10−6M SB225002. (C) hCXCR2–G204A,C352I
Gαi2 or hI148E CXCR2–C352I Gαi2 were expressed transiently in HEK-293 cells. Following
pertussis-toxintreatment(25 ng/mlfor16h)andmembranepreparation,bindingof[35S]GTP[S]
in Gαi2 immunoprecipitates was measured in the absence of ligand (Basal) or the presence of
3×10−7MI L - 8( I L - 8 )o r1 0 −6M DADLE (DADLE). Values are means+ −S.E.M. (n=3).
for SB225002 (Figure 5D). These effects were not restricted to
DADLE. Entirely analogous effects of SB225002 were observed
when either a second synthetic enkephalin, DPDPE (Figure 5D),
or the non-peptide ligand SNC162 [28] (Figure 5D) were used as
agonists at the DOP receptor.
Because of the ability to control c-Myc–I148E hCXCR2–
C352I Gαi2 expression in these cells in the face of
constitutive expression of FLAG–hDOP–G204A,C352I Gαi2,w e
therefore examined the time course of induction of c-Myc–
I148E hCXCR2–C352I Gαi2 expression following addition of
doxycycline (1 μg/ml) to these cells. Immunoblotting cell lysates
with an anti-c-Myc antibody conﬁrmed a lack of expression of
this polypeptide without doxycycline treatment (Figure 6A). c-
Myc–I148E h CXCR2–C352I Gαi2 expression could be detected
within 6 h of doxycycline treatment, but at that time the fusion
protein was present largely as an immature form that lacked
terminalN-glycosylation(Figure6A).By24 h,higherlevelsofc-
Myc–I148E hCXCR2–C352I Gαi2 were present and a substantial
amount of this polypeptide was terminally N-glycosylated. This
pattern was maintained in the presence of doxycycline for up
to at least 96 h (Figure 6A). Levels of FLAG–hDOP–G204A,
C352I Gαi2 expression were unaffected by the induction of
c-Myc–I148E hCXCR2–C352I Gαi2 expression (Figure 6A).
As anticipated, without doxycycline treatment, DADLE could
not stimulate binding of [
35S]GTP[S] in membranes of these
cells following pertussis-toxin treatment, whereas with time of
doxycycline treatment, both the capacity of DADLE to elevate
binding of [
35S]GTP[S] in Gαi2 immunoprecipitates and the effect
of SB225002 to enhance G-protein activation in response to
DADLE mirrored the time course of appearance of c-Myc–I148E
hCXCR2–C352I Gαi2 immunoreactivity (Figure 6B).
Although a highly effective means to explore these receptor
co-expression-dependent heterodimer-speciﬁc [25,44] allosteric
effects of CXCR2 antagonists on DOP receptor function, the fu-
sionproteinsareartiﬁcialconstructions[45,46].Hence,toexplore
these effects further we generated extra Flp-In T-REx HEK-293
celllinesinwhichhCXCR2N-terminallytaggedwithVSV-Gwas
cloned into the inducible locus and in which FLAG–hDOP
wasexpressedconstitutively.Asanticipated,anti-FLAGimmuno-
cytochemistry demonstrated the presence of FLAG–hDOP
both without and with treatment of the cells with doxycycline
(Figure 7A). In contrast, anti-VSV-G immunoreactivity was
only detected following treatment of the cells with doxycycline
(Figure 7A) and merging of the images indicated co-localization
of VSV-G–hCXCR2 and FLAG–hDOP at the cell surface (Fig-
ure 7A). In membranes derived from both untreated and doxycyc-
line-treated cells, DADLE-stimulated binding of [
35S]GTP[S]
was blocked by the general opioid receptor antagonist naloxone
(Figure 7B). However, although DADLE-stimulated binding of
[
35S]GTP[S] in membranes of untreated cells was unaffected by
SB225002 (Figure 7B), in doxycycline-treated cells SB225002
again enhanced the capacity of DADLE (10
−6M) to promote
binding of [
35S]GTP[S] (Figures 7B and 7C) and did so in a con-
centration-dependent manner with a pEC50 =−8.1 (Figure 7C).
IL-8 stimulated binding of [
35S]GTP[S] only in membraness
of doxycycline-treated cells and, in contrast with the effect of
DADLE, SB225002 blocked the effect of IL-8, whereas naloxone
was without effect (Figure 7C).
DISCUSSION
GPCRs are the most tractable class of therapeutic targets for the
design and development of small-molecule therapeutic medicines
and it has been estimated that some 30–50% of clinically
available drugs target the function of GPCR family members
[47,48]. All but two of the medicines that interact directly with
a GPCR do so via the orthosteric binding site, i.e. the binding
site for the natural ligand, and function either to mimic or block
the action of the natural ligand [25]. Despite this, and due in part
to the clinical effectiveness of cinacalcet, that acts as a positive
allosteric modulator of the Ca
2+-sensing receptor [49,50], and
the recent development of the anti-HIV medicine maraviroc that
acts as a CCR5 receptor-directed negative allosteric regulator
[25,51], there is now considerable interest in understanding the
basis and mode of action of ligands that bind to allosteric sites on
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Figure 5 Inducible expression of c-Myc-I148E–CXCR2–C352I Gαi2 in the presence of FLAG–hDOP-G204A,C352I Gαi2 results in their co-localization at the
surface of Flp-In T-REx HEK-293 cells and G-protein activation by DADLE
(A) Flp-In T-REx HEK-293 cells were generated that harboured c-Myc-I148E–CXCR2–C352I Gαi2 at the Flp-In locus and constitutively expressed FLAG–hDOP–C352I Gαi2. Cells were treated with
(lowerpanels)orwithout(upperpanels)doxycycline(1μg/ml,48h).FLAG–hDOP–C352IGαi2 (green)wasdetectedusinganti-FLAGandc-Myc–I148E-CXCR2–C352IGαi2 (red)withanti-CXCR2.
Mergedimagesarealsoshown(right-handpanels).(B)Flp-InT-RExHEK-293cellsasin(A)weretreated(+Dox)ornot(−Dox)withdoxycycline(1μg/ml,48h)andwithpertussistoxin(25ng/ml)
for the last 16h. Membranes of these cells were used to measure binding of [35S]GTP[S] in Gαi2 immunoprecipitates in the absence (open bars) and presence (solid bars) of DADLE (10−6M).
∗∗P <0.001, signiﬁcantly greater after treatment with doxycycline (measured using the paired t test. (C) Membranes of the above doxycycline- and pertussis-toxin-treated Flp-In T-REx HEK-293
cells were used to measure binding of [35S]GTP[S] in Gαi2 immunoprecipitates in response to varying concentrations of DADLE () and DADLE+10−6M SB225002 (). ∗∗P <0.001, signiﬁcant
enhancement in the presence of SB225002 (measured using one-way ANOVA). (D) Membranes as above were used to measure binding of [35S]GTP[S] in Gαi2 immunoprecipitates in the presence
of 10−6M DADLE (), DPDPE () or SNC162 () and various concentrations of SB225002. Values are means+ −S.E.M. (n=3).
GPCRs [52–54]. This reﬂects, in part, that true allosteric ligands
are anticipated to function only in the presence of an orthosteric
agonist and to modulate the effectiveness of signal transduction.
To date, virtually all studies on allosteric regulators of GPCRs
have focused on modulators that bind to the same GPCR as
the orthosteric ligand but at a separate location. This reﬂects a
combinationofthetraditionalviewthatGPCRsexistandfunction
as non-interacting monomeric species and that ligand screening
strategiesconcentrateonanalysisofthefunctionofasingleGPCR
expressed in isolation.
It is now widely accepted that GPCRs can form dimers and/or
higher-order oligomers and that dimerization is probably integral
to function [16,55]. Although the majority of early studies
concentrated on homodimerization, i.e. interactions between
multiple copies of the same GPCR, there has been a growing base
of evidence to support the concept that GPCR heterodimerization
can occur and that it is relevant to physiological function. Given
the widespread co-expression of many GPCRs, such ‘hetero-
dimers’ are being considered as novel sets of therapeutic targets.
Indeed, as the multiplicity of opioid receptor pharmacologies
in vivo are far too complex to be explained by individual
monomers, or indeed homodimers, of the molecularly deﬁned
DOP, KOP and MOP receptors, there is a large literature on
how opioid receptor heterodimerization may help to explain
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Figure 6 The effect of SB225002 requires expression of hCXCR2
Flp-In T-REx HEK-293 cells that harboured c-Myc–I148E-CXCR2–C352I Gαi2 at the Flp-In
locusandconstitutivelyexpressedFLAG–hDOP–C352IGαi2 weretreatedforvarioustimeswith
doxycycline(1μg/ml).Followingpertussis-toxintreatmentandmembranepreparation,samples
wereresolvedbySDS/PAGEandimmunoblotted(A)todetectc-Myc–I148E-CXCR2–C352IGαi2
(upper panel) or FLAG–hDOP–C352I Gαi2 (lower panel). (B) Membranes of these cells were
then used to assess basal binding (open bars) of [35S]GTP[S] in Gαi2 immunoprecipitates
and the effects of DADLE (10−6M; light-grey bars) or DADLE+SB225002 (both at 10−6M;
black bars). ∗P <0.01, ∗∗P <0.001 (as compared with control; measured using one-way
ANOVA).
this complex pharmacology [56,57]. Furthermore, based on the
co-expression patterns of opioid receptor subtypes, apparently
orthosteric ligands have been reported to show considerable
selectivity for speciﬁc opioid receptor heterodimer pairings [58].
In a GPCR heterodimer, it might be anticipated that the binding
of a ligand to the orthosteric site of one GPCR could alter the
pharmacology and function of the orthosteric binding site of
the partner GPCR [25]. In such a situation the ligand at the
ﬁrst GPCR would act as an allosteric agent for the orthosteric
agonist of the second GPCR and this would be a heterodimer-
speciﬁc effect [25] because the ligand would display no direct
effect on the second GPCR in assays in which the second GPCR
was expressed alone. This concept has important implications
for the design, identiﬁcation and use of novel small-molecule
regulators of GPCRs. For example, the allosteric effect of such
ligandswouldberestrictedtocellsandtissuesinwhichtheGPCR
heterodimer is present and would only be detected in assays in
which the relevant target GPCR heterodimer is present [25].
Figure 7 Production and characterization of Flp-In T-REx HEK-293 cells
harbouring VSV-G–hCXCR2 and constitutively expressing FLAG–hDOP:
SB225002 enhances the function of an opioid agonist in cells co-expressing
hDOP and hCXCR2
(A) Flp-In T-REx HEK-293 cell lines were created in which hCXCR2 which was N-terminally
tagged with VSV-G was cloned into the inducible locus and in which FLAG–hDOP was
expressed constitutively. Cells were treated with (lower panels) or without (upper panels)
doxycycline(1μg/ml,48h).Anti-FLAGimmunocytochemistry(red)demonstratedthepresence
of FLAG–hDOP both without and with treatment of the cells with doxycycline. In contrast,
anti-VSV-G immunoreactivity (green) was only detected following treatment of the cells
with doxycycline. Merging of the images (right-hand panels) indicated co-localization of
VSV-G–hCXCR2 and FLAG–hDOP (yellow) at the cell surface when both constructs were
expressed.(B)MembranesofFlp-InT-RExHEK-293cellsasin(A)wereusedbothwithout(open
bars)orfollowingdoxycyclineinductionofVSV-G–hCXCR2expression(solidbars)tomeasure
theabilityofDADLE(10−6M),DADLE(10−6M)+SB225002(10−6M),DADLE(10−6M)+nal-
oxone (10−5M), IL-8 (10−8M), IL-8 (10−8M)+SB225002 (10−6M) or IL-8 (10−8M)+
naloxone(10−5M)toenhancebasalbindingof[35S]GTP[S]. ∗∗SB225002enhancestheeffectof
DADLE(P <0.001); =,SB225002doesnothaveasigniﬁcanteffect.(C)Followingdoxycycline
induction of VSV-G–hCXCR2 expression, membranes as above were used to measure binding
of [35S]GTP[S] in response to DADLE (10−6M) in the presence of various concentrations of
SB225002.
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Although this concept has not been explored widely, there are a
numberofreportsconsistentwithsuchamechanism.Forexample,
incellsco-expressingtheCCR2bandCCR5chemokinereceptors
CCR5-speciﬁc ligands that are unable to compete for MCP-1
binding on cells expressing CCR2b alone, and hence presumable
do not bind directly to CCR2b, were able to prevent efﬁciently
MCP-1 binding when the two receptors were co-expressed [26].
In a similar vein, binding of the agonist [
125I]melatonin to the
MT1 receptor was eliminated when the orphan GPCR GPR50
was co-expressed along with the melatonin MT1 receptor [27].
Furthermore, in cells natively co-expressing GPR50 and the
MT1 receptor, speciﬁc [
125I]melatonin binding could not be
observed until GPR50 levels were reduced via a siRNA (small
interfering RNA)-based approach [27]. GPR50 is related to the
MT1 receptor and these workers also provided a series of observ-
ations consistent with their heterodimerization [27]. Perhaps even
more interesting from a therapeutic standpoint, the cannabinoid
CB1 receptor orthosteric antagonist/inverse agonist rimonabant
(marketedasAcomplia
TM),whichhasbeenapprovedinEuropefor
the treatment of obesity, decreases the potency of the orexigenic
peptide orexin A only when the cannabinoid CB1 receptor is co-
expressed with the orexin-1 receptor [33] and these two GPCRs
effectively form a heterodimer [33].
As noted earlier, opioid receptors are widely expressed by
white blood cells and there is a substantial literature on functional
interactions between opioid ligands and chemokines in the regul-
ation of white-cell chemotaxis. Prior to the present studies there
have also been reports of direct physical interactions between
opioid and chemokine receptors. Previously, these have concen-
trated on the CCR5 receptor due to its role as a co-receptor
for HIV-1 entry into CD4
+ white cells and the susceptibility of
opiate addicts to succumb to HIV-1 infection. Furthermore, very
recent studies by Pello et al. [59] have shown that interactions
between the chemokine CXCR4 receptor and the DOP receptor
have functional consequences in immune cells in that co-addition
of agonist ligands for these receptors fail to generate function,
leading to a suppression of signalling potentially because the
heterodimer produces a dominant-negative effect.
Therefore our initial studies centred on obtaining evidence
for physical interactions between the CXCR2 receptor and the
DOP opioid receptor. This was achieved by a combination of
co-immunoprecipitation and various intact cell resonance energy
transfer techniques, whereas the use of so-called ‘saturation’
BRET studies [36,37] suggested that CXCR2 receptor–DOP
opioid receptor hetero-interactions may display higher avidity
than either corresponding homo-interaction. This concept is not
without parallel. Work on melatonin receptor subtypes has indi-
cated greater avidity of hetero-interactions between the MT1 and
MT2 receptors than the corresponding MT1–MT1 or MT2–MT2
homo-interactions [60].
For a number of years we [38,39] and others (see [61,62] for
review) have employed fusion proteins, in which a G-protein α
subunit is linked in-frame to the C-terminal tail of a GPCR to
generate chimaeric, bi-functional polypeptides to explore many
aspects of GPCR and G-protein function and pharmacology. We
havealsousedthisapproachtoexamineGPCRhomodimerization
by demonstrating reconstitution of function only upon co-expres-
sion of pairs of GPCR–G-protein fusions that are individually
inactive [30,63]. When we co-expressed pairs of such fusion
proteinsinwhich,intheﬁrst,theCXCR2receptorwasnotsignal-
transduction-competent because of the introduction of a mutation
into the second intracellular loop, whereas in the second the DOP
receptor was wild-type but the linked G-protein was modiﬁed to
prevent guanine-nucleotide exchange, DOP agonists were able
tocauseactivationofthewild-typeG-proteinlinkedtotheCXCR2
receptor in a concentration-dependent manner. Furthermore,
following co-expression of this pairing, a CXCR2 antagonist
was able to enhance the maximal activity of a range of DOP
receptor agonists with distinct chemotypes. We also attempted
to explore whether the CXCR2 agonist IL-8 also modulated the
function or potency of DOP receptor agonists. However, we were
unable to observe such effects (results not shown). The reasons
for this are unclear. It could be hypothesized that an agonist
ligand might have a greater effect on the structure/function of
the partner GPCR of the heterodimer because agonist ligands
must alter the conformation of their own target receptor to initiate
signaltransduction.Suchaneffectmightthenaltertheorthosteric
binding pocket or function of the GPCR heterodimer partner.
However, it is impractical at this stage to speculate on the basis
or implications of our inability to detect such an effect, not least
because of the size and structural differences between the peptide
agonist IL-8 and the synthetic small-molecule CXCR2 blocker
employed.
Key experiments employed Flp-In T-REx HEK-293 cells.
These contain a single site of chromosomal integration from
which constructs cloned into this locus can be expressed in
a completely inducible fashion. In these studies c-Myc–I148E
CXCR2–C352I Gαi2 was harboured at the Flp-In locus, whereas
inthesamecellsFLAG–hDOP–G204A,C352IGαi2 wasexpressed
stably and constitutively. Antibiotic-induced turn-on of c-Myc–
I148E CXCR2–C352I Gαi2 expression was required to observe
both DOP receptor function and the positive allosteric effects
of the CXCR2 antagonist on this. Initial preliminary studies had
conﬁrmedthattheDOPligandshadnodirecteffectattheCXCR2
receptorandthattheCXCR2antagonisthadnodirecteffectsatthe
DOP receptor, indicating the allosteric effects to be heterodimer
speciﬁc. Importantly, as well as requiring expression of CXCR2,
the allosteric effects of the CXCR2 antagonist were produced in a
concentration-dependent fashion and with afﬁnity consistent with
its occupancy of the CXCR2 orthosteric binding site.
Although these key experiments were performed using pairs
of GPCR–G-protein fusions it is important to note that entirely
equivalent results were produced when Flp-In T-REx HEK-293
cells were established in which the unfused wild-type hDOP
receptor was expressed constitutively and the unfused mutant
hCXCR2 receptor could be produced, on demand, from the Flp-
In T-REx locus.
The present studies provide clear biochemical, biophysical and
nowpharmacologicalevidencetoindicatethecapacityofCXCR2
andDOPopioidreceptorsto interactphysically.Theyalsoclearly
indicate the capacity of GPCR heterodimers to provide novel
allosteric pharmacology. Detection of such activities in ligand
screening campaigns will be a challenge because they will be
identiﬁed by neither primary screens, nor secondary counter
screens, in which individual GPCRs are expressed and studied
‘one target at a time’ [25]. However, such heterodimer speciﬁc
allosteric ligands offer obvious opportunities, modulating the
function of the partner GPCR only in the presence of the ortho-
stericligandforthatreceptoranddoingsoonlyincellsandtissues
in which the relevant heterodimer is expressed [25]. It will be
interesting to see if this principle can be exploited therapeutically.
These studies were supported by the BBSRC (Biosciences and Biotechnology Research
Council), Cara Therapeutics and the Wellcome Trust.
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